리드리스 페이스메이커 시장 규모, 점유율, 동향 분석 : 챔버별, 브랜드별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Leadless Pacemakers Market Summary

The global leadless pacemakers market size was estimated at USD 982.42 million in 2025 and is projected to reach USD 1,622.87 million by 2033, growing at a CAGR of 6.56% from 2026 to 2033. The increasing prevalence of cardiac disorders and associated risk factors is expected to drive demand for advanced device-based therapies.

According to an Oxford Academic article published in January 2025, globally, the age-standardized prevalence of cardiovascular disease is estimated at approximately 7,179 cases per 100,000 people, emphasizing the significant and growing burden of cardiac conditions. This high prevalence has amplified the need for innovative pacing solutions to manage rhythm disorders more safely and effectively. Leadless pacemakers have emerged as a transformative advancement in this field, offering a minimally invasive alternative to traditional pacemakers by eliminating the need for leads and surgical pockets. Leadless pacemakers (PMs) have become a well-established therapeutic option over the past decade, offering significant advantages over traditional transvenous pacemakers. According to the NCBI article published in April 2025, eliminating leads and subcutaneous pockets, leadless devices such as Micra and Aveir substantially reduce the risk of infections and long-term complications such as electrode dislocation, pocket hematomas, pneumothorax, endocarditis, and venous obstruction. Data from the Micra PAR registry, which followed 1,809 patients for a mean of 51 months, reported a five-year major complication rate of only 4.5%, with most occurring within 30 days of implantation. Notably, no infections required device removal, and system revisions were rare, primarily for device upgrades or battery depletion.

Technological advances have further expanded the use of leadless pacemakers. VDD(R) pacing in Micra AV and DDD(R) pacing in Aveir DR enable synchronized atrioventricular pacing, allowing treatment of a broader patient population, including those with high infection risk, limited vascular access, or prior device infections. Long-term data also demonstrate stable electrical performance and battery longevity, with over 95% of devices remaining functional at five years. Compared with historical transvenous cohorts, leadless PMs show a 53% reduction in major complications and system revisions, making them a safer and increasingly preferred choice for patients requiring long-term pacing therapy.

Global Leadless Pacemakers Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global leadless pacemakers market report based on chambers, brands, end use, and region:

• Chambers Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
• Single Chamber
• Dual Chamber
• Brands Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
• Micra VR and VR2
• Micra AV and AV2
• Abbott Aveir DR
• Abbott Aveir VR
• Abbott Aveir AR
• End Use Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
• Hospitals
• Outpatient Facilities
• Regional Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology And Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Leadless Pacemakers Market: Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Chambers Outlook
  • 2.2.2. Brands Outlook
  • 2.2.3. End Use Outlook
• 2.3. Competitive Insights

Chapter 3. Leadless Pacemakers Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cardiovascular diseases & other heart ailments
    • 3.2.1.2. Reduced risk of infection and complications compared to traditional pacemakers
    • 3.2.1.3. Technological advancements in electrophysiology & ineffective pharmacological treatments
    • 3.2.1.4. Growing patients demand for minimally invasive procedures
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost hampers widespread adoption of leadless pacemakers
    • 3.2.2.2. Higher mortality risk
• 3.3. Global Leadless Pacemakers: Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTLE Analysis
• 3.4. Case Study Analysis
• 3.5. Patient Epidemiology & Adoption Analysis (Comparative Analysis: 2023 vs 2024 vs 2025)
  • 3.5.1. Eligible Patient Pool for Leadless Pacing (2023 Vs 2024 Vs 2025)
  • 3.5.2. Patients Actually Receiving Leadless Pacemakers (2023 Vs 2024 Vs 2025)
  • 3.5.3. Non-Implant / Contraindicated Population (2023 Vs 2024 Vs 2025)
  • 3.5.4. Non-Implant / Contraindicated Population (2023 Vs 2024 Vs 2025)
  • 3.5.5. Comparative Safety & Complication Rates (2023 Vs 2024 Vs 2025)
  • 3.5.6. Patient Demographics & Comorbidity Mix (2023 Vs 2024 Vs 2025)
• 3.6. Technology Trends for Leadless Pacemakers Market
• 3.7. Competitive Factors and Strategies
  • 3.7.1. Product Improvements & Innovations
  • 3.7.2. Emerging Technologies

Chapter 4. Leadless Pacemakers Market Segment Analysis, By Chambers 2021-2033 (USD Million), Unit Volume (In Thousand)

• 4.1. Definition and Scope
• 4.2. Chambers Market Share Analysis, 2025 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Leadless Pacemakers Market, By Chambers, 2021 - 2033
• 4.5. Leadless Pacemakers Market Size & Forecasts, By Chambers, 2021 - 2033 (USD Million)
• 4.6. Leadless Pacemakers Market Size & Forecasts, By Chambers, Unit Volume, 2021 - 2033 (In Thousand Units)
  • 4.6.1. Single Chamber
    • 4.6.1.1. Single Chamber Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 4.6.2. Dual Chamber
    • 4.6.2.1. Dual Chamber Market Estimates and Forecasts 2021 To 2033 (USD Million)

Chapter 5. Leadless Pacemakers Market Segment Analysis, By Brands 2021-2033 (USD Million), Unit Volume (In Thousand)

• 5.1. Definition and Scope
• 5.2. Brands Market Share Analysis, 2025 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Leadless Pacemakers Market By Brands Outlook
• 5.5. Leadless Pacemakers Market Size & Forecasts, By Brands, 2021 - 2033 (USD Million)
• 5.6. Leadless Pacemakers Market Size & Forecasts, By Brands, Unit Volume, 2021 - 2033 (In Thousand Units)
• 5.7. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For the Following
  • 5.7.1. Micra VR and VR2
    • 5.7.1.1. Micra VR and VR2 Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 5.7.2. Micra AV and AV2
    • 5.7.2.1. Micra AV and AV2 Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 5.7.3. Abbott Aveir DR
    • 5.7.3.1. Abbott Aveir DR Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 5.7.4. Abbott Aveir VR
    • 5.7.4.1. Abbott Aveir VR Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 5.7.5. Abbott Aveir AR
    • 5.7.5.1. Abbott Aveir AR Market Estimates and Forecasts 2021 To 2033 (USD Million)

Chapter 6. Leadless Pacemakers Market Segment Analysis, By End Use 2021-2033 (USD Million)

• 6.1. Definition and Scope
• 6.2. End Use Market Share Analysis, 2025 & 2033
• 6.3. Segment Dashboard
• 6.4. Global Leadless Pacemakers Market By End Use Outlook
• 6.5. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For the Following
  • 6.5.1. Hospitals
    • 6.5.1.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 6.5.2. Outpatient Facilities
    • 6.5.2.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)

Chapter 7. Leadless Pacemakers Market Segment Analysis, By Region, 2021-2033 (USD Million)

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Leadless Pacemakers Market Share by Region, 2025 & 2033:
• 7.5. North America
  • 7.5.1. North America Leadless Pacemakers Market, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. U.S. Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.5.2.5. U.S. Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Canada Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.5.3.5. Canada Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Mexico Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.5.4.5. Mexico Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
• 7.6. Europe
  • 7.6.1. Europe Leadless Pacemakers Market, 2021 To 2033 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. UK Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.6.2.5. UK Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Germany Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.6.3.5. Germany Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.6.4. Spain
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Spain Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.6.4.5. Spain Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.6.5. France
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. France Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.6.5.5. France Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.6.6. Italy
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Italy Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.6.6.5. Italy Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.6.7. Denmark
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Denmark Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.6.7.5. Denmark Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Sweden Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.6.8.5. Sweden Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.6.9. Norway
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Competitive Scenario
    • 7.6.9.3. Regulatory Framework
    • 7.6.9.4. Norway Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.6.9.5. Norway Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Competitive Scenario
    • 7.7.1.3. Regulatory Framework
    • 7.7.1.4. Japan Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.7.1.5. Japan Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.7.2. China
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. China Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.7.2.5. China Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.7.3. India
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. India Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.7.3.5. India Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.7.4. South Korea
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. South Korea Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.7.4.5. South Korea Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.7.5. Thailand
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Thailand Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.7.5.5. Thailand Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.7.6. Australia
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Australia Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.7.6.5. Australia Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
• 7.8. Latin America
  • 7.8.1. Latin America Leadless Pacemakers Market, 2021 - 2033 (USD Million)
  • 7.8.2. Brazil
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Brazil Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.8.2.5. Brazil Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.8.3. Argentina
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Argentina Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.8.3.5. Argentina Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
• 7.9. MEA
  • 7.9.1. MEA Leadless Pacemakers Market, 2021 - 2033 (USD Million)
  • 7.9.2. South Africa
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. South Africa Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.9.2.5. South Africa Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Saudi Arabia Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.9.3.5. Saudi Arabia Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.9.4. UAE
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Competitive Scenario
    • 7.9.4.3. Regulatory Framework
    • 7.9.4.4. UAE Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.9.4.5. UAE Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Competitive Scenario
    • 7.9.5.3. Regulatory Framework
    • 7.9.5.4. Kuwait Leadless Pacemakers Market, 2021 To 2033 (USD Million)
    • 7.9.5.5. Kuwait Leadless Pacemakers Market, Unit Volume, 2021 To 2033 (In Thousand Units)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Profiles
  • 8.3.1. Abbott
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Product benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Medtronic
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. EBR Systems, Inc.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Boston Scientific Corporation
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. MicroPort Scientific Corporation.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives